TheProfitWatch

ALT - Altimmune, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
4.6 0.26 (5.65%) 0.0 (0.1%) 0.0 (0.0%) 0.11 (2.32%) -0.1 (-2.17%) 0.4 (8.97%) 0.02 (0.44%) 0.05 (1.11%)

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Category: PHARMACEUTICAL PREPARATIONS
Market Period: Market

Earnings & Ratios

Basic EPS:
-0.27
Diluted EPS:
-0.27
Basic P/E:
-18.0
Diluted P/E:
-18.0
RSI(14) 1m:
55.55
VWAP:
4.86
RVol:

Events

Period Kind Movement Occurred At

Related News